Horizon Pharma Inc. (HZNP) Short Interest Update
Horizon Pharma Inc. (NASDAQ:HZNP) was the recipient of a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 17,130,318 shares, an increase of 8.4% from the August 31st total of 15,809,119 shares. Approximately 11.2% of the shares of the stock are short sold. Based on an average trading volume of 3,565,429 shares, the days-to-cover ratio is currently 4.8 days.
A number of equities research analysts have commented on HZNP shares. Stifel Nicolaus reissued a “buy” rating and set a $45.00 price objective on shares of Horizon Pharma in a report on Wednesday, July 6th. Goldman Sachs Group Inc. reissued a “buy” rating and set a $27.00 price objective on shares of Horizon Pharma in a report on Tuesday. Brean Capital reissued a “buy” rating and set a $30.00 price objective on shares of Horizon Pharma in a report on Thursday, July 14th. Zacks Investment Research lowered shares of Horizon Pharma from a “buy” rating to a “hold” rating in a report on Thursday, August 11th. Finally, Mizuho reissued a “buy” rating and set a $30.00 price objective (up previously from $24.00) on shares of Horizon Pharma in a report on Wednesday, August 10th. One analyst has rated the stock with a sell rating, three have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $30.00.
Shares of Horizon Pharma (NASDAQ:HZNP) opened at 18.78 on Thursday. Horizon Pharma has a 12 month low of $12.86 and a 12 month high of $23.70. The company has a 50 day moving average of $19.99 and a 200-day moving average of $17.66. The firm’s market capitalization is $3.02 billion.
Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.12. The business earned $257.40 million during the quarter, compared to the consensus estimate of $235.43 million. Horizon Pharma had a positive return on equity of 23.46% and a negative net margin of 0.34%. Horizon Pharma’s revenue for the quarter was up 48.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.39 earnings per share. Analysts predict that Horizon Pharma will post $2.15 EPS for the current year.
In other Horizon Pharma news, EVP Jeffrey W. Sherman sold 2,900 shares of the stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $20.00, for a total transaction of $58,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 2.10% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Fund Advisors increased its position in Horizon Pharma by 127.3% in the second quarter. BlackRock Fund Advisors now owns 6,678,136 shares of the biopharmaceutical company’s stock worth $109,989,000 after buying an additional 3,740,449 shares during the period. State Street Corp boosted its position in Horizon Pharma by 149.1% in the second quarter. State Street Corp now owns 4,201,164 shares of the biopharmaceutical company’s stock worth $69,194,000 after buying an additional 2,514,430 shares in the last quarter. Deerfield Management Co. boosted its position in Horizon Pharma by 17.6% in the first quarter. Deerfield Management Co. now owns 13,740,261 shares of the biopharmaceutical company’s stock worth $227,676,000 after buying an additional 2,055,460 shares in the last quarter. Fiera Capital Corp acquired a new position in Horizon Pharma during the second quarter worth about $28,892,000. Finally, BlackRock Institutional Trust Company N.A. boosted its position in Horizon Pharma by 57.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 3,673,204 shares of the biopharmaceutical company’s stock worth $60,498,000 after buying an additional 1,335,251 shares in the last quarter. 85.25% of the stock is owned by institutional investors and hedge funds.
About Horizon Pharma
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
Receive News & Stock Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related stocks with our FREE daily email newsletter.